Please assess the completion status of the following clinical trial:

Trial Title: Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged ≥ 18 years~* Coronary artery disease with a clinically diagnosed peripheral neuropathy~* Willing and able to provide signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization~* Willing and able to comply with the requirements of the protocol and follow directions from the clinic staff~Exclusion Criteria:~* History of allergy or intolerance to ranolazine~* Any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see Appendix E)~* In the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug~* In the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition)~* Use of any experimental or investigational drug or device within 30 days prior to screening~* Pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of birth control (as detailed in Inclusion Criterion 4)~* Had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization~* Clinically significant hepatic impairment~* Had end-stage renal disease requiring dialysis~* Psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation~* Positive pregnancy test at Baseline (pre-randomization, Day 0)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo-Ranolazine (Type: EXPERIMENTAL): Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
- Ranolazine-Placebo (Type: EXPERIMENTAL): Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).